Inhibiting TIGIT/CD155 signaling has shown promise in reversing the exhaustion of CD8+ T cells and boosting the effectiveness of anti-tumor treatments in both cervical cancer and multiple myeloma [17,87]. This evidence concerns the gene CD8A and cervical carcinoma.